Integra LifeSciences (NASDAQ:IART) Updates FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.410-2.510 for the period, compared to the consensus estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its FY25 guidance to $2.41 to $2.51 EPS.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on IART. Citigroup boosted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley began coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target for the company. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Performance

Integra LifeSciences stock traded down $0.40 during midday trading on Thursday, reaching $23.21. 223,228 shares of the stock traded hands, compared to its average volume of 600,608. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $41.17. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -255.92, a PEG ratio of 0.73 and a beta of 1.17. The firm has a fifty day moving average price of $23.74 and a two-hundred day moving average price of $21.84. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same period in the previous year, the firm earned $0.89 EPS. Integra LifeSciences’s revenue was up 11.5% on a year-over-year basis. On average, equities research analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.10% of the stock is owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.